Table 1.

Projected Timeline of the Three Critical Criteria

		Future
	Now	Intermediate	Far
Benefit	Low: Our body of knowledge about genetic risk and disease variants is still relatively shallow. We do not have enough data to estimate the probability of clinical benefit for any individual.	High: A large body of knowledge about the disease risk from specific variants has accumulated. Genomic analysis is likely to yield clinically beneficial information for any individual.	High: A large body of knowledge about the disease risk from specific variants has accumulated. Genomic analysis is likely to yield clinically beneficial information for any individual.
Uniqueness of access	High: Access to genomic sequencing and analysis is available almost exclusively through research.	High: Access to genomic sequencing and analysis is available almost exclusively through research.	Low: Genomic sequencing and analysis is widely available through standard clinical care.
Burden	High: Considerable time, effort and resources are needed to manually evaluate a large number of potentially significant variants.	Low: Technological advances make identifying significant variants in a genome simple and efficient.	Low: Technological advances make identifying significant variants in a genome simple and efficient.